Please ensure Javascript is enabled for purposes of website accessibility Global Life Sciences Fund - Janus Henderson Investors - Asia China PI (EN)
{{banner.link_text}}
For Approved Qualified Domestic Institutional Investors in China

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.

ISIN
IE00BFTCP959

NAV
CNH 27.46
As of 2026/02/10

1-Day Change
CNH -0.07 (-0.25%)
 As of 2026/02/10

Overview

Investment objective

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Less

About this fund

  • Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
  • An experienced team of specialists that seeks to understand the science and the business of health care

Portfolio Management

Andy Acker, CFA: Portfolio Manager
Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA: Portfolio Manager | Research Analyst
Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Cumulative Performance (%)
As of 2026/01/31
A2 HCNH (Net) MSCI World Health Care NR
 
  Cumulative
  1MO 3MO 6MO YTD 1YR 3YR 5YR Since Inception
2014/10/03
A2 HCNH (Net) 0.47 8.97 27.76 0.47 13.50 21.72 26.35 175.70
MSCI World Health Care NR 0.68 5.84 14.43 0.68 4.01 26.13 47.38 174.59
Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.
Calendar Year Returns (%)
As of 2025/12/31
A2 HCNH (Net) MSCI World Health Care NR
2025 2024 2023 2022 2021
A2 HCNH (Net) 19.36 -1.08 2.70 -4.31 7.35
MSCI World Health Care NR 9.17 4.27 6.78 2.91 17.27
Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.

Recommended holding period 5 Years

Example Investment: CNH 100,000

Scenarios If you exit after 1 year If you exit after 5 years
MinimumThere is no minimum guaranteed return. You could lose some or all of your investment
StressWhat you might get back after costs42,400 CNH33,360 CNH
Average return each year-57.60%-19.71%
UnfavourableWhat you might get back after costs79,580 CNH97,150 CNH
Average return each year-20.42%-0.58%
ModerateWhat you might get back after costs104,430 CNH150,490 CNH
Average return each year4.43%8.52%
FavourableWhat you might get back after costs134,320 CNH212,810 CNH
Average return each year34.32%16.31%
There is currently insufficient data to provide a useful indication of past performance to investors.
Fee Information
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 2024/12/31) 		2.39%
The ongoing charge is calculated using the Packaged Retail Investment Product (PRIIPs) methodology. The PRIIPs methodology differs to the UCITS ongoing charge methodology, as the PRIIPS methodology captures additional recurring charges, including but not limited to: a. Interest paid on borrowing (e.g. bank interest) b. Any fees incurred in relation to stock-lending activity (i.e. the fee paid to the lending agent) c. Any costs associated with holding closed-ended vehicles.
Please refer to the offering documents for more details on the fees and expenses.

Portfolio

Top Holdings (As of 2025/12/31)
% of Fund
Eli Lilly & Co 9.67
Johnson & Johnson 5.58
AstraZeneca PLC 4.27
UnitedHealth Group Inc 3.44
AbbVie Inc 3.39
Abbott Laboratories 2.64
Argenx SE (ADR) 2.64
Novartis AG (ADR) 2.51
Praxis Precision Medicines Inc 2.38
Boston Scientific Corp 2.35
TOTAL 38.87
Portfolio holdings are subject to change without notice. 
Sector allocation (%) % of Fund % of Index % of Fund % of Index As of 2025/12/31
Market Capitalization Range of Equity Holdings % of Fund % of Index % of Fund % of Index As of 2025/12/31
Country/Geographic Exposures % of Fund % of Index % of Fund % of Index As of 2025/12/31
Regional Allocation % of Fund % of Index % of Fund % of Index As of 2025/12/31

Documents

Related Insights

Differentiated insights are central to our investment approach.

JH Explorer: Takeaways from the 2026 J.P. Morgan Healthcare Conference
10 Feb 2026
Timely & Topical

JH Explorer: Takeaways from the 2026 J.P. Morgan Healthcare Conference

After attending the sector’s flagship conference, we come away with strengthened conviction in the constructive backdrop shaping healthcare in 2026.

Read More

Why healthcare stocks could excel in 2026
2 Dec 2025
Features & Outlooks

Why healthcare stocks could excel in 2026

Andy Acker and Dan Lyons explain why low valuations and improving fundamentals could help the healthcare sector stand out in 2026.

Read More

Playing the long game in biotech’s recovery
18 Nov 2025
Timely & Topical

Playing the long game in biotech’s recovery

The biotech sector has rebounded from a sharp sell-off earlier this year and could deliver even more value to investors who know where to look.

Read More

Choose region

Country

Language

What type of investor are you?